154 related articles for article (PubMed ID: 25495249)
1. Supervised clustering of immunohistochemical markers to distinguish atypical and non-atypical endometrial hyperplasia.
Laas E; Ballester M; Cortez A; Gonin J; Canlorbe G; Daraï E; Graesslin O
Gynecol Endocrinol; 2015 Apr; 31(4):282-5. PubMed ID: 25495249
[TBL] [Abstract][Full Text] [Related]
2. Supervised clustering of immunohistochemical markers to distinguish atypical endometrial hyperplasia from grade 1 endometrial cancer.
Laas E; Ballester M; Cortez A; Gonin J; Daraï E; Graesslin O
Gynecol Oncol; 2014 May; 133(2):205-10. PubMed ID: 24556060
[TBL] [Abstract][Full Text] [Related]
3. Analysis of PTEN, estrogen receptor α and progesterone receptor expression in endometrial hyperplasia using tissue microarray.
Pieczyńska B; Wojtylak S; Zawrocki A; Biernat W
Pol J Pathol; 2011 Sep; 62(3):133-8. PubMed ID: 22102068
[TBL] [Abstract][Full Text] [Related]
4. Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium.
Obokata A; Watanabe J; Nishimura Y; Arai T; Kawaguchi M; Kuramoto H
Anticancer Res; 2007; 27(1A):95-105. PubMed ID: 17352221
[TBL] [Abstract][Full Text] [Related]
5. Localization of MT1-MMP, TIMP-1, TIMP-2, and TIMP-3 messenger RNA in normal, hyperplastic, and neoplastic endometrium. Enhanced expression by endometrial adenocarcinomas is associated with low differentiation.
Määttä M; Soini Y; Liakka A; Autio-Harmainen H
Am J Clin Pathol; 2000 Sep; 114(3):402-11. PubMed ID: 10989641
[TBL] [Abstract][Full Text] [Related]
6. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study.
Graesslin O; Cortez A; Fauvet R; Lorenzato M; Birembaut P; Daraï E
Ann Oncol; 2006 Apr; 17(4):637-45. PubMed ID: 16407419
[TBL] [Abstract][Full Text] [Related]
7. Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2): a novel biomarker for the identification of atypical hyperplasia and Type I endometrial carcinoma.
Buell-Gutbrod R; Cavallo A; Lee N; Montag A; Gwin K
Int J Gynecol Pathol; 2015 Jan; 34(1):65-73. PubMed ID: 25473755
[TBL] [Abstract][Full Text] [Related]
8. Endometrial hyperplasia-related inflammation: its role in the development and progression of endometrial hyperplasia.
Kubyshkin AV; Aliev LL; Fomochkina II; Kovalenko YP; Litvinova SV; Filonenko TG; Lomakin NV; Kubyshkin VA; Karapetian OV
Inflamm Res; 2016 Oct; 65(10):785-94. PubMed ID: 27312112
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature.
Rakha E; Wong SC; Soomro I; Chaudry Z; Sharma A; Deen S; Chan S; Abu J; Nunns D; Williamson K; McGregor A; Hammond R; Brown L
Am J Surg Pathol; 2012 Nov; 36(11):1683-90. PubMed ID: 23073327
[TBL] [Abstract][Full Text] [Related]
10. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
[TBL] [Abstract][Full Text] [Related]
11. Endometrial TIMP-4 mRNA is high at midcycle and in hyperplasia, but down-regulated in malignant tumours. Coordinated expression with MMP-26.
Pilka R; Domanski H; Hansson S; Eriksson P; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):641-50. PubMed ID: 15273280
[TBL] [Abstract][Full Text] [Related]
12. [Activity of matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9) and content of their tissue inhibitors in endometrial cancer--a preliminary study].
Bogusiewicz M; Stryjecka-Zimmer M; Rechberger T
Ginekol Pol; 2007 May; 78(5):366-72. PubMed ID: 17867327
[TBL] [Abstract][Full Text] [Related]
13. Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias.
Masuzawa H; Badokhon NH; Nakayama K; Konishi I; Nikaido T; Fujii S
Cancer; 1994 Oct; 74(8):2321-8. PubMed ID: 7922983
[TBL] [Abstract][Full Text] [Related]
14. [Expressions of aromatase protein and sex hormone receptor in endometrial lesions].
Ma XX; Zhang SL; Gao S; Lu JM; Dong F
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):395-8. PubMed ID: 16831363
[TBL] [Abstract][Full Text] [Related]
15. Endometrial Stromal Expression of ER, PR, and B-Catenin Toward Differentiating Hyperplasia Diagnoses.
Chatzipantelis P; Koukourakis M; Balaska K; Giatromanolaki A
Int J Surg Pathol; 2022 Aug; 30(5):492-498. PubMed ID: 34866456
[No Abstract] [Full Text] [Related]
16. Role of Morphometry and Matrix Metalloproteinase-9 Expression in Differentiating between Atypical Endometrial Hyperplasia and Low Grade Endometrial Adenocarcinoma.
Assaf MI; Abd El-Aal W; Mohamed SS; Yassen NN; Mohamed EA
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2291-2297. PubMed ID: 30139240
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
18. Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding.
Galant C; Berlière M; Dubois D; Verougstraete JC; Charles A; Lemoine P; Kokorine I; Eeckhout Y; Courtoy PJ; Marbaix E
Am J Pathol; 2004 Jul; 165(1):83-94. PubMed ID: 15215164
[TBL] [Abstract][Full Text] [Related]
19. IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA.
Socolov D; Socolov R; Lupascu IA; Rugina V; Gabia O; Garauleanu DM; Carauleanu A
Rev Med Chir Soc Med Nat Iasi; 2016; 120(2):355-62. PubMed ID: 27483717
[TBL] [Abstract][Full Text] [Related]
20. Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions.
Graesslin O; Cortez A; Uzan C; Birembaut P; Quereux C; Daraï E
Int J Gynecol Cancer; 2006; 16(5):1911-7. PubMed ID: 17009991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
